These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 31419875)

  • 1. Economic Perspectives on Personalized Health Care and Prevention.
    Phillips KA; Sakowski JA; Liang SY; Ponce NA
    Forum Health Econ Policy; 2013 Sep; 16(2):S23-S52. PubMed ID: 31419875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opportunities in the Economics of Personalized Health Care and Prevention.
    Meltzer DO
    Forum Health Econ Policy; 2013 Sep; 16(2):S13-S22. PubMed ID: 31419870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized medicine and the role of health economics and outcomes research: issues, applications, emerging trends, and future research.
    O'Donnell JC
    Value Health; 2013; 16(6 Suppl):S1-3. PubMed ID: 24034305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group.
    Faulkner E; Annemans L; Garrison L; Helfand M; Holtorf AP; Hornberger J; Hughes D; Li T; Malone D; Payne K; Siebert U; Towse A; Veenstra D; Watkins J;
    Value Health; 2012 Dec; 15(8):1162-71. PubMed ID: 23244820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reflections on market access for personalized medicine: recommendations for Europe.
    Payne K; Annemans L
    Value Health; 2013; 16(6 Suppl):S32-8. PubMed ID: 24034310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "What Goes Around Comes Around": Lessons Learned from Economic Evaluations of Personalized Medicine Applied to Digital Medicine.
    Phillips KA; Douglas MP; Trosman JR; Marshall DA
    Value Health; 2017 Jan; 20(1):47-53. PubMed ID: 28212968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Some economics on personalized and predictive medicine.
    Antoñanzas F; Juárez-Castelló CA; Rodríguez-Ibeas R
    Eur J Health Econ; 2015 Dec; 16(9):985-94. PubMed ID: 25381039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized medicine policy challenges: measuring clinical utility at point of care.
    van Rooij T; Wilson DM; Marsh S
    Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):289-95. PubMed ID: 22812553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current methodological issues in the economic assessment of personalized medicine.
    Annemans L; Redekop K; Payne K
    Value Health; 2013; 16(6 Suppl):S20-6. PubMed ID: 24034308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health technology assessment and personalized medicine: are economic evaluation guidelines sufficient to support decision making?
    Husereau D; Marshall DA; Levy AR; Peacock S; Hoch JS
    Int J Technol Assess Health Care; 2014 Apr; 30(2):179-87. PubMed ID: 24806420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decision Making on Medical Innovations in a Changing Health Care Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies.
    Trosman JR; Weldon CB; Douglas MP; Deverka PA; Watkins JB; Phillips KA
    Value Health; 2017 Jan; 20(1):40-46. PubMed ID: 28212967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value-Based Pricing and Reimbursement in Personalised Healthcare: Introduction to the Basic Health Economics.
    Garrison LP; Towse A
    J Pers Med; 2017 Sep; 7(3):. PubMed ID: 28869571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Just caring: assessing the ethical and economic costs of personalized medicine.
    Fleck LM
    Urol Oncol; 2014 Feb; 32(2):202-6. PubMed ID: 24445288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives on health economics. 3. Economics in action.
    Mooney G; Yule B
    Fam Pract; 1985 Mar; 2(1):4-9. PubMed ID: 2859230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncotyrol--Center for Personalized Cancer Medicine: Methods and Applications of Health Technology Assessment and Outcomes Research.
    Siebert U; Jahn B; Rochau U; Schnell-Inderst P; Kisser A; Hunger T; Sroczynski G; Mühlberger N; Willenbacher W; Schnaiter S; Endel G; Huber L; Gastl G;
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):330-40. PubMed ID: 26354133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges to the translation of genomic information into clinical practice and health policy: Utilization, preferences and economic value.
    Phillips KA; Liang SY; Van Bebber S;
    Curr Opin Mol Ther; 2008 Jun; 10(3):260-6. PubMed ID: 18535933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical and health economic challenges of personalized medicine].
    Brüggenjürgen B; Kornbluth L; Ferrara JV; Willich SN
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2012 May; 55(5):710-4. PubMed ID: 22526860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3].
    Lakdawalla DN; Doshi JA; Garrison LP; Phelps CE; Basu A; Danzon PM
    Value Health; 2018 Feb; 21(2):131-139. PubMed ID: 29477390
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.